Filana Therapeutics, Inc. SAVAW
At closeAug 19, 2024, 4:00 PM EDT
- Market cap
- 1.45M
- Volume
- 2.51M
- Avg volume
- 331.00K
- Open
- 0.1035
- Previous close
- 0.03
- Day's range
- 0.03 – 0.03
- 52-week range
- 0.02 – 11.02
- Beta
- -0.58
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.01
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -82.64M
- Total cash
- 148.98M
- Total debt
- 0
- Return on equity
- -10.98%
- Short % of float
- 0.00%
- 50-day average
- 3.49
- 200-day average
- 4.93
Next earnings
Consensus EPS estimate 0.00.
About Filana Therapeutics, Inc.
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
- Country
- United States
- Website
- cassavasciences.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on SAVAW — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Cutler Group LP | 0.01% | 1,120 | 33 | Mar 30, 2024 |
| IFP Advisors, Inc | 0.00% | 105 | 3 | Jun 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Price (T.Rowe) U.S. Small Cap Index Trust | 0.02% | 3,062 | 91 | Mar 30, 2024 |